<DOC>
	<DOC>NCT01042106</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of DSP-8658 in patients with Type 2 diabetes mellitus and healthy adults.</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Diabetic subjects Age ≥ 18 and ≤ 65 years Body Mass Index ≤45 Drug naive type 2 diabetes or type 2 diabetes previously treated with an oral antidiabetic drug Healthy subjects Age ≥ 18 and ≤ 65 years Body Mass Index ≥ 18 and ≤ 29 Good health as determined by medical history, ECG, clinical chemistry, hematology, urinalysis, virology, and a physical examination. Diabetic subjects Have a current or expected requirement for any antidiabetic or lipidlowering drug Healthy subjects Have, or have had a history of clinically significant neurological, urological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders including cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>diabetes</keyword>
</DOC>